Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck

Anticancer Research

Volumn 16, Issue 4 C, 1996, Pages 2385-2388

  Lavieille, Jean Pierre ^a   Lubin, Richard ^b   Soussi, Thierry ^b   Reyt, Emile ^a   Brambilla, Christian ^c   Riva, Catherine ^a,d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c INSTITUT ALBERT BONNIOT   (France)

^d HÔPITAL MICHALLON   (France)

Author keywords

Head and neck tumor; p53 antibodies; Prognosis

Indexed keywords

ANTIBODY; PARAFFIN; PROTEIN P53;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; HYPOPHARYNX; IMMUNOHISTOCHEMISTRY; LARYNX; MAJOR CLINICAL STUDY; OROPHARYNX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

EID: 0029831120     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer - a review. Int J Cancer 57: 1-9, 1994.
2. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL and Casey, G: Frequent p53 mutations in head and neck cancer. Cancer Res 52: 5997-6000, 1992.
3. Ahomadegbe JC, Barrois M, Fogel S, Lebihan ML, Doucrasy S, Duvillard P, Armand JP and Riou G: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome, frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10: 1217-1227, 1995.
4. Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D and Weichselbaum RR: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 52: 4832-4836, 1992.
5. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA and Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712-717, 1995.
6. Boyle JO, Hakim J, Koch W, Vanderriet P. Hruban RH, Roa RA, Correo R, Eby YJ Ruppert JM and Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480, 1993.
7. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild C and Soussi T: p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clinical Cancer Res 1: 1463-1469, 1995.
8. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487, 1994.
9. Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Fursiainen K, and Vainino H: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 64: 176-181, 1995.
10. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
11. Davidoff AM, Iglehart JD and Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442, 1992.
12. Lavieille JP, Brambilla E, Riva-Lavieille C, Reyt E, Charachon R and Brambilla C: Immunohistochemical detection of p53 protein in preneoplastic lesions and squamous cell carcinoma of the head and neck. Acta Otolaryngol. (Stockh) 115: 334-339, 1995.
13. Tenaud C, Negoescu A, Labatmoleur F, Legros Y, Soussi T and Brambilla E: Methods in pathology - p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Modern Pathol 7: 853-859, 1994.
14. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS and Gluckman JL: The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 119: 1118-1122, 1993.
15. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, Schumann A and Bosch FX: Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 53: 4189-4196, 1993.
16. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, Romanelli M and Borocchi M: p53 overexpression is an early event in the development of human squamous cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52: 178-182, 1992.
17. Shin D, Kim J, Ro J et Hittelman J, Roth JA, Hong WK and Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 321-326, 1994.
18. Munck-Wikland E, Edstrom S, Jungmark E, Kuylensterna R, Lindholm J and Auer G: Nuclear DNA content, proliferating-cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions. Int J Cancer 56: 95-99, 1994.
19. Caamano J, Zhang SY, Rosvold EA, Bauer B and Klein-Szanto AJP: p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 142: 1131-1139, 1993.
20. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J and Soussi T: Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621-622, 1995.
21. Field JK, Malliri A and Butt SA: p53 overexpression in end stage squamous cell carcinomas of the head and neck correlates with a very poor clinical outcome. Int J Oncol 3: 431-435, 1993.